0.9071
6.70%
0.0371
시간 외 거래:
.96
0.0529
+5.83%
전일 마감가:
$0.87
열려 있는:
$0.89
하루 거래량:
542.63K
Relative Volume:
1.88
시가총액:
$1.02M
수익:
-
순이익/손실:
$-9.34M
주가수익비율:
-0.0999
EPS:
-9.0833
순현금흐름:
$-6.69M
1주 성능:
-41.62%
1개월 성능:
-54.09%
6개월 성능:
-91.59%
1년 성능:
-96.02%
패인리폼 Stock (PRFX) Company Profile
패인리폼 주식(PRFX)의 최신 뉴스
PainReform Ltd. Launches Warrant Exercise Incentive Program - TipRanks
PainReform confirms sutures compatibility for in trial for PRF-110 - TipRanks
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 - GlobeNewswire
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 - StockTitan
Ratio Analysis: Unpacking PainReform Ltd (PRFX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
PainReform to issue new warrants in stock exercise deal By Investing.com - Investing.com Australia
PainReform Shares Are Trading Lower Today: What's Going On - Benzinga
PRFX stock touches 52-week low at $1.17 amid steep annual decline - Investing.com
PRFX stock touches 52-week low at $1.17 amid steep annual decline - Investing.com UK
PainReform to issue new warrants in stock exercise deal - Investing.com
PainReform to issue new warrants in stock exercise deal By Investing.com - Investing.com Canada
PainReform to issue new warrants in stock exercise deal By Investing.com - Investing.com UK
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds - GlobeNewswire
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds - StockTitan
Holdings of PainReform Ltd (PRFX) are aligned with the stars - SETE News
PainReform Ltd [PRFX] is -90.64% lower this YTD. Is it still time to buy? - The DBT News
Upcoming Stock Splits This Week (September 9 to September 13) – Stay InvestingTHE BHARAT EXPRESS NEWS - The Bharat Express News
PainReform Ltd: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
PainReform Ltd (PRFX) stock analysis: A simple moving average approach - US Post News
PainReform Ltd’s Mixed Bag: Down -90.20% in 6 Months, Down -38.34% in 30 Days - The InvestChronicle
PainReform Announces Reverse Share Split - TipRanks
Market Momentum: PainReform Ltd (PRFX) Registers a -4.21 Decrease, Closing at 0.22 - The Dwinnex
PainReform (NASDAQ:PRFX) Shares Down 11.7% - Defense World
PRFX stock touches 52-week low at $0.24 amid sharp annual decline - Investing.com
Market Insight: PainReform Ltd (PRFX)’s Notable Gain, Closing at 0.27 - The Dwinnex
The time has not yet come to remove your chips from the table: PainReform Ltd (PRFX) - SETE News
PainReform Ltd. Schedules 2024 Annual Meeting - TipRanks
Do investors need to be concerned about PainReform Ltd (PRFX)? - US Post News
Prepare Yourself for Liftoff: PainReform Ltd (PRFX) - SETE News
PainReform reports breakthrough in post-surgical pain management - Investing.com India
PainReform reports breakthrough in post-surgical pain management - Investing.com
PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures - Yahoo Finance
PainReform Bunionectomy Study Observations Confirm Optimal - GlobeNewswire
Ratios Reveal: Breaking Down PainReform Ltd (PRFX)’s Financial Health - The Dwinnex
PainReform reports safety data from Phase III bunionectomy trial of PRF-110 - Yahoo Finance
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com India
PainReform reports positive early safety data in Phase 3 study - Investing.com India
PainReform Ltd: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
PainReform reports positive early safety data in Phase 3 study - Investing.com
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com Canada
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com Australia
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com UK
PRFX Stock Earnings: PainReform Beats EPS for Q2 2024 - MSN
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study - GlobeNewswire
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study - StockTitan
PainReform announces safety profile for PRF-110 in Phase 3 study - TipRanks
PRFX (PainReform) Cyclically Adjusted Book per Share : $0.00 (As of Mar. 2024) - GuruFocus.com
PainReform Reports Significant Asset Decline - TipRanks
PainReform Provides Business Update for the Second Quarter of 2024 - GlobeNewswire
PainReform Provides Business Update for the Second Quarter of 2024 - StockTitan
패인리폼 (PRFX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):